Immunotherapy for Esophageal Cancer
This is a news story, published by NBC News, that relates primarily to Maureen Sideris news.
Maureen Sideris news
For more Maureen Sideris news, you can click here:
more Maureen Sideris newsdisease research news
For more disease research news, you can click here:
more disease research newsNBC News news
For more news from NBC News, you can click here:
more news from NBC NewsAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
esophageal cancer. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Cancer surgery news, other cancer treatments news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
gastroesophageal cancerNBC News
•Health
Health
For some cancer patients, immunotherapy may be way to skip surgery and chemo
86% Informative
Maureen Sideris , 71 , was diagnosed with gastroesophageal cancer in 2022 .
She received immunotherapy as part of a clinical trial at Memorial Sloan Kettering .
The trial focused on people whose tumors had what’s known as mismatch repair deficiency.
Mismatch repair deficiency occurs more frequently in some cancers than others.
Study: 49 patients who completed six months of immunotherapy didn't need surgery, chemotherapy or radiation.
About 75% of the patients were still cancer-free a year or more after completing the treatment.
The research suggests immunotherapy could possibly be used as a first -line treatment for early-stage mismatch repair deficient cancers.
VR Score
89
Informative language
89
Neutral language
61
Article tone
informal
Language
English
Language complexity
49
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Affiliate links
no affiliate links